Loading...
XNASNSPR
Market cap74mUSD
Dec 26, Last price  
2.87USD
1D
0.35%
1Q
4.36%
Jan 2017
-100.00%
IPO
-100.00%
Name

InspireMD Inc

Chart & Performance

D1W1MN
XNAS:NSPR chart
P/E
—
P/S
12.06
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
279.65%
Rev. gr., 5y
11.50%
Revenues
6m
+20.00%
006,004,0005,349,0004,873,0002,818,0002,310,0001,894,0002,761,0003,601,0003,721,0002,485,0004,495,0005,171,0006,205,000
Net income
-20m
L+7.71%
-3,825-23,976-14,665,000-17,597,000-29,258,000-25,095,000-15,585,000-8,461,000-8,438,000-7,240,000-10,040,000-10,544,000-14,918,000-18,491,000-19,916,000
CFO
-16m
L+5.37%
-825-18,981-6,003,000-8,580,000-10,300,000-19,362,000-11,596,000-7,495,000-8,131,000-7,606,000-9,810,000-9,081,000-13,210,000-15,542,000-16,376,000
Earnings
Mar 04, 2025

Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
URL
https://www.inspiremd.com/en/
IPO date
Apr 12, 2013
Employees
55
Domiciled in
IL
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,205
20.00%
5,171
15.04%
4,495
80.89%
Cost of revenue
27,348
23,884
19,211
Unusual Expense (Income)
NOPBT
(21,143)
(18,713)
(14,716)
NOPBT Margin
Operating Taxes
65
28
45
Tax Rate
NOPAT
(21,208)
(18,741)
(14,761)
Net income
(19,916)
7.71%
(18,491)
23.95%
(14,918)
41.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
37,534
(140)
35,034
BB yield
-55.04%
2.07%
-157.92%
Debt
Debt current
557
419
420
Long-term debt
2,633
2,390
1,982
Deferred revenue
Other long-term liabilities
1,084
995
1,052
Net debt
(35,833)
(14,994)
(31,638)
Cash flow
Cash from operating activities
(16,376)
(15,542)
(13,210)
CAPEX
(381)
(473)
(344)
Cash from investing activities
(16,092)
8,441
(22,457)
Cash from financing activities
37,534
(140)
35,034
FCF
(7,980)
(32,789)
(14,761)
Balance
Cash
39,023
17,803
34,040
Long term investments
Excess cash
38,713
17,544
33,815
Stockholders' equity
(221,499)
(201,584)
(183,093)
Invested Capital
263,679
221,586
218,878
ROIC
ROCE
EV
Common stock shares outstanding
24,268
7,872
7,346
Price
2.81
226.93%
0.86
-71.54%
3.02
-40.94%
Market cap
68,194
907.91%
6,766
-69.50%
22,185
186.86%
EV
32,361
(8,228)
(9,453)
EBITDA
(20,911)
(18,525)
(14,555)
EV/EBITDA
0.44
0.65
Interest
28
157
Interest/NOPBT